Voyager Therapeutics, Inc. (NasdaqGS: VYGR)
Health Care · Biotechnology · US
$2.27
-7.35% today · -53.6% 1Y
Voyager Therapeutics, Inc. (NasdaqGS: VYGR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $139.87M and employs 141 people.
Over the last twelve months the share price has lost 53.6%, trading between 2.33 and 5.55.
Tweenvest scores Voyager Therapeutics, Inc. across four factors: quality 39/100, value 59/100, growth 0/100. Its strongest factor is value.
VYGR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $139.87M
- Revenue (TTM)
- $34.46M
- P/E
- —
- EPS
- -1.81
- Dividend yield
- —
- Beta (5Y)
- 1.28
- 52-week high
- $5.55
- 52-week low
- $2.33
- Avg volume (3M)
- —
- Shares outstanding
- 61.62M
- Employees
- 141
- Next earnings
- —
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
- ISIN
- US92915B1061
- Founded
- 2013
- Listed since
- Nov 11, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| UnicoCell Biomed Co., Ltd.TWSE: 6794 | $142.50M | NT$71.60 | -9.25% |
| Outlook Therapeutics, Inc.NasdaqCM: OTLK | $142.44M | $0.59 | +0.24% |
| Cloudbreak Pharma Inc.SEHK: 2592 | $140.32M | HK$— | — |
| Anavex Life Sciences Corp.NasdaqGS: AVXL | $139.97M | $1.51 | +1.34% |
| 3billion, Inc.KOSDAQ: A394800 | $139.66M | ₩5,900.00 | -2.32% |
| NeoImmuneTech, Inc.KOSDAQ: A950220 | $139.14M | ₩1,892.00 | -4.69% |
| Korro Bio, Inc.NasdaqCM: KRRO | $137.98M | $9.37 | -7.78% |
| Armata Pharmaceuticals, Inc.NYSEAM: ARMP | $134.97M | $3.58 | -1.38% |
Figures last refreshed Oct 11, 2026.